Navigation Links
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies

hout causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.

"These new data reaffirm the broad potential and versatility of our Vascular Targeting Agent platform for cancer therapy," said Steven W. King, president and CEO of Peregrine. "We have long thought that our anti- phospholipid antibodies would be ideal for the delivery of cytokines for cancer therapy based on their inherent immunostimulatory effects combined with the anti-tumor effects of the cytokines themselves. We are especially pleased with the strong anti-tumor activity observed in a model of B-cell lymphoma, the first non-solid cancer we have successfully addressed using our VTA technology. We are now assessing our options to further develop and commercialize these cytokine fusion proteins for cancer and potentially, viral infections."

The new class of fusion protein agents falls under Peregrine's VTA technology platform for cancer therapy that includes over 200 patents and patent applications covering broad concepts of tumor therapy using agents that target tumor blood vessels. Because interferon is currently part of standard- of-care therapy for virus infections including chronic hepatitis C, Peregrine also intends to assess the utility of the new class as a second-generation treatment for viral infections.

This work was supported by Susan G. Komen for the Cure and a sponsored research agreement with Peregrine Pharmaceuticals Inc.

Number 3539: Inhibition of Tumor Growth by Targeting Cytokines to Phosphatidylserine (PS) on Tumor Vascular Endothelium, Xianming H
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/30/2015)... What can be expected from ... going to grow at the fastest rates? Visiongain ... 2025, assessing data, trends, opportunities and prospects there. ... charts, and graphs. Discover the most lucrative areas in ... study lets you assess forecasted sales at overall world ...
(Date:7/30/2015)... BURLINGAME, Calif. , July 30, 2015 /PRNewswire/ ... Patent and Trademark Office has granted the company ... property covering Cleave,s lead molecule CB-5083. ... quinazolines as inhibitors of p97," U.S. 9,062,026, allows ... CB-5083, a first-in-class, highly selective oral inhibitor of ...
(Date:7/30/2015)... Ohio, July 30, 2015  Cardinal Health today ... billion, an increase of 20 percent, and non-GAAP ... of $1.00, an increase of 20 percent. Non-GAAP ... On a GAAP basis, operating earnings increased 44 ... continuing operations increased 29 percent to $0.88. ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31
... Safety and Reduce Health Care CostsBETHESDA, Md., May 7 ... pilot program, contributing data on adverse events associated with ... will be possible to identify best practices that can ... overall costs to the health care system.This pilot hemovigilance ...
... Society Annual Meeting-BALTIMORE, May 7 Arcion Therapeutics, ... that develops pain therapies, today announced the presentation ... significantly reduced pain caused by diabetic neuropathy in ... presented in a poster session on May 8th ...
Cached Medicine Technology:National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 2Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 3
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... been consistently growing into one of the largest, family-owned low cost service and ... residential and commercial applications, as well as growing their company to meet the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Center,” to announce its position as one of Medicare’s top-rated care centers. ... members support the CMS rating system, which monitors health inspections, staffing, and ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, ... of Medicine as Assistant Professor of Plastic Surgery. This is Dr. Clevens’ second ... worked closely with the university, developing a strong presence and a valuable mentoring program ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Using ... eradicate suicide and teach people more effective ways to prevent and manage major depression. ... to react fast enough, so people fall through the cracks and die needlessly everyday,” ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Between ... according to the Health News Florida on June 17th. Those untreated heroin ... exchange programs to prevent the spread of dirty needles throughout the community. Ultimately Florida’s ...
Breaking Medicine News(10 mins):Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Beachside Nursing Center Releases New Video 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... does not appear to pose a severe occupational hazard for ... syndrome, according to a Danish study published Tuesday.,The finding was ... locations who were questioned initially on symptoms and 5,568 of ... This study found a prevalence ...
... effective breast cancer treatment. That's the suggestion put forward by ... June issue of the Journal of Clinical Cancer Research. The ... mice, adds to a growing body of evidence that a ... powerful anti-cancer properties,// particularly when combined with radiation therapy. ,When ...
... the American Cancer Society, there are 172,000 Americans diagnosed with ... tests, many of these cancers are caught in their later ... now helping patients who have failed standard treatment. ,By going ... Studies show as many as 20 percent of patients //taking ...
... salmon, tuna or bluefish twice a week can prevent ... long been known that eating fish is associated with ... researchers had scientific evidence to explain the effect. Researchers ... detailed explanation of how omega-3 fish oils benefit the ...
... of Hong Kong and,the Shenzhen Disease Prevention and Control Center,have ... observed form a study conducted on ten random workers at ... were found to have SARS antibodies, proving the presence of ... thus suggesting that the workers had a mild infection. ...
... may benefit non-anemic women between ages 18 and 55 with ... with low ferritin, a protein that stores iron and is ... of Lausanne in Switzerland gave 136 women either 80 milligrams ... The study shows the level of fatigue after one month ...
Cached Medicine News:Health News:Longer Lung Cancer Survival 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: